GR69741B - - Google Patents

Info

Publication number
GR69741B
GR69741B GR62506A GR800162506A GR69741B GR 69741 B GR69741 B GR 69741B GR 62506 A GR62506 A GR 62506A GR 800162506 A GR800162506 A GR 800162506A GR 69741 B GR69741 B GR 69741B
Authority
GR
Greece
Application number
GR62506A
Other languages
Greek (el)
Inventor
Harald Furrer
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of GR69741B publication Critical patent/GR69741B/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GR62506A 1979-07-21 1980-01-28 GR69741B (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792929596 DE2929596A1 (de) 1979-07-21 1979-07-21 Verfahren zur herstellung von oxoalkyl-xanthinen

Publications (1)

Publication Number Publication Date
GR69741B true GR69741B (https=) 1982-07-12

Family

ID=6076378

Family Applications (1)

Application Number Title Priority Date Filing Date
GR62506A GR69741B (https=) 1979-07-21 1980-01-28

Country Status (9)

Country Link
EP (1) EP0023032A1 (https=)
JP (1) JPS5616486A (https=)
AR (1) AR227645A1 (https=)
DE (1) DE2929596A1 (https=)
DK (1) DK311580A (https=)
ES (1) ES8105005A1 (https=)
FI (1) FI802267A7 (https=)
GR (1) GR69741B (https=)
NO (1) NO802173L (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157098A1 (en) * 1980-06-21 1985-10-09 Beecham Wuelfing GmbH & Co KG Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment
GB8501488D0 (en) * 1985-01-21 1985-02-20 Beecham Group Plc Treatment
US4851060A (en) * 1987-08-12 1989-07-25 Essex Group, Inc. Multilayer wrapped insulated magnet wire
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336403A1 (fr) * 1975-12-24 1977-07-22 Bruneau & Cie Lab Nouveau procede de preparation de l'acide (theophyllinyl-7)-3 propanesulfonique
GB1527543A (en) * 1976-04-15 1978-10-04 Degussa Basically substituted xanthine derivatives
DE2714953C2 (de) * 1977-04-02 1986-09-25 Hoechst Ag, 6230 Frankfurt Arzneimittel

Also Published As

Publication number Publication date
FI802267A7 (fi) 1981-01-01
EP0023032A1 (de) 1981-01-28
ES493385A0 (es) 1981-05-16
DE2929596A1 (de) 1981-02-05
ES8105005A1 (es) 1981-05-16
AR227645A1 (es) 1982-11-30
DK311580A (da) 1981-01-22
JPS5616486A (en) 1981-02-17
NO802173L (no) 1981-01-22

Similar Documents

Publication Publication Date Title
BR8002583A (https=)
BR8006808A (https=)
AT364253B (https=)
AU78390S (https=)
AU78569S (https=)
AU78270S (https=)
AU78271S (https=)
AU78385S (https=)
AU78386S (https=)
AU78389S (https=)
AU77669S (https=)
AU78391S (https=)
AU77763S (https=)
AU79200S (https=)
AU79557S (https=)
AU79558S (https=)
BR5901094U (https=)
AU79826S (https=)
AU79918S (https=)
AU79950S (https=)
AU80228S (https=)
AU79559S (https=)
BG28376A1 (https=)
BG28729A1 (https=)
BG28229A1 (https=)